Melanoma therapy
US6923966B2 · kind B2 · utility
7Cited by
16References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 12, 2001 |
| Grant date | Aug 2, 2005 |
| Priority date | — |
| Expiry date | Jul 12, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/212
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods for treating treatment-naive as well as treatment-experienced patients having melanoma to increase the progression-free survival time involving administering a therapeutically effective amount of pegylated interferon-alpha, e.g., preferably pegylated interferon alpha-2b, as adjuvant therapy to definitive surgery are disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.